News
Thu, 02 Nov 2023 05:25:00 -0400
Thu, 02 Nov 2023 05:25:00 -0400
Financial report for the period 1 January 2023 to 30 September 2023
|
PROFIT AND LOSS |
9M 2023 |
9M 2022 |
Growth as reported |
Growth at CER* |
|
USD million |
|
|
|
|
|
Net sales |
24,404 |
18,406 |
29% |
33% |
|
Operating profit |
11,027 |
8,245 |
31% |
37% |
|
|
|
|
|
|
|
Net profit |
8,978 |
5,990 |
47% |
N/A |
|
Diluted earnings per share (in USD) |
1.99 |
1.32 |
49% |
N/A |
|
* CER: Constant exchange rates (average 2022). ** For convenience, Danish kroner has been translated to USD in this release, using the average exchange rate of USD 1.0 = DKK 6.87478 and the period-end exchange rate of USD 1.0 = DKK 7.03898. |
||||
Lars Fruergaard Jørgensen, president and CEO: "We are very satisfied with the sales growth in the first nine months of 2023, which is reflecting that more people than ever are benefiting from our innovative diabetes and obesity treatments. Within R&D, we are pleased with the decision to stop the FLOW kidney outcomes trial early as semaglutide demonstrated a benefit in people with type 2 diabetes and chronic kidney disease. The acquisition of ocedurenone for the treatment of cardiovascular disease supports our aspiration of establishing a presence in other serious chronic diseases with high unmet medical needs."
On 2 November 2023 at 13.00 CET, corresponding to 08.00 am EDT, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under ‘Investors’.